Add
INSM to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| INSM > SEC Filings for INSM > Form 8-K on 10-Nov-2008 | All Recent SEC Filings |
10-Nov-2008
Entry into a Material Definitive Agreement, Financial Statements and Exhibits
On November 8, 2008, Genentech and Ipsen/Tercica signed a letter of intent whereby they have consented to amend the March 7, 2007 Court-Ordered Settlement, Development and License Agreement (the "Agreement") between Genentech, Inc. ("Genentech") Tercica, Inc. ("Tercica") and Insmed Incorporated ("Insmed") to permit Insmed to supply IPLEX™ in connection with named-patient ALS programs worldwide on a royalty-free basis. Insmed's ability to do so will be dependent on satisfying any regulatory requirements in any country where a request for treatment is made.
On November 10, 2008 Insmed issued a Press Release announcing a joint statement from Genentech, Ipsen/Tercica and Insmed stating that Insmed had gained royalty-free worldwide rights for IPLEX™ from Genentech and Ipsen/Tercica in connection with potential Named Patient (Expanded Access) Programs for ALS. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
(d) Exhibits
99.1 Press Release, dated November 10 2008
|
|